Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

INDIANAPOLIS (AP) — Eli Lilly is pouring another $4.5 billion ... its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. Those drugs have funneled fresh revenue to Lilly and ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...